NGL FINECHEM
|
The Current P/E Ratio of NGL FINECHEM is 41.23.
| Share Price | ₹3,194.9 | Jul 24,2026 |
| Market Cap | ₹1,980.8 Cr | |
| Earnings-TTM | ₹48.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 41.23x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NGL FINECHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,980.8 Cr] as on Jul 24,2026
(/) Earnings [ ₹48.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 41.23x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay 41.23 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NGL FINECHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NGL FINECHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of NGL FINECHEM
PE Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 28.31x.
- NGL FINECHEM 's operated at median p/e ratio of 31.37x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2023 at 36.22x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2021 of 16.74x.
How does NGL FINECHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NGL FINECHEM | 48.04 | 41.23 | 1,980.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 40.27 | 465,711.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 74.91 | 192,376.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 88.24 | 188,655.0 |
| CIPLA LTD | 3,364.84 | 33.87 | 113,979.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 30.36 | 96,204.7 |
| MANKIND PHARMA LTD | 1,926.41 | 53.71 | 103,472.0 |
| LUPIN LTD | 5,355.47 | 20.23 | 108,340.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.01 | 110,613.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 25.17 | 88,119.1 |
| LAURUS LABS LTD | 1,090.76 | 79.36 | 86,564.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NGL FINECHEM 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 20.23x |
| Max industry PE | 88.24x |
| Median industry PE | 40.27x |
| Average industry PE | 46.31x |
You may also like the below Video Courses